1-9 of 9
Anita Szoke
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Surzetoclax (ABBV-453) in combination with daratumumab and dexamethasone in biomarker-selected patients with Relapsed/Refractory multiple myeloma: A Phase 1/2, multicenter, open-label platform study

Free
John McKay, Hang Quach, Matthew Pianko, Shonali Midha, Jorge Chaves, Kevin Kelly, Hila Magen, Yaël Cohen, Moshe Gatt, Noa Lavi, Adeel Khan, Silvia Ling, Iuliana Vaxman, Sabrina Browning, Xin Chen, Michelle Gillard, Anita Szoke, Lynne Neumayr, Maria Semerjian, Agostino Pozzi, Saad Usmani
Journal: Blood
Blood (2025) 146 (Supplement 1): 5844.
https://doi.org/10.1182/blood-2025-5844
Published: 2025
Journal Articles

First-line ibrutinib + venetoclax shows benefit across genomic subgroups in patients with chronic lymphocytic leukemia (CLL): Results from Phase 2 captivate study and Phase 3 glow study

Free
Leo Cheung, Shiquan Wu, Brendan Hodkinson, Constantine Tam, William Wierda, Paolo Ghia, Anita Szoke, Edith Szafer Glusman
Journal: Blood
Blood (2025) 146 (Supplement 1): 5672.
https://doi.org/10.1182/blood-2025-5672
Published: 2025
Journal Articles

Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL

Open Access
Clinical Trials & Observations
Jan A. Burger, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Alessandra Tedeschi, Anita Sarma, Piers E. M. Patten, Sebastian Grosicki, Helen McCarthy, Fritz Offner, Edith Szafer-Glusman, Cathy Zhou, Anita Szoke, Lynne Neumayr, James P. Dean, Paolo Ghia, Thomas J. Kipps
Journal: Blood
Blood (2025) 146 (18): 2168–2176.
https://doi.org/10.1182/blood.2024028205
Published: 2025
Includes: Supplemental data
Journal Articles

Consistently High 5.5-Year Progression-Free Survival (PFS) Rates in Patients with and without Bulky Baseline Lymphadenopathy ≥5 Cm Are Associated with High Undetectable Minimal Residual Disease (uMRD4) Rates after First-Line Treatment with Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in the Phase 2 CAPTIVATE Study

Free
William G. Wierda, Ryan Jacobs, Paul M Barr, John N. Allan, Tanya Siddiqi, Alessandra Tedeschi, Thomas J. Kipps, Susan M. O'Brien, Xavier C. Badoux, Andrea Visentin, Masa Lasica, Dennis A. Carney, Anna Elinder Cambrun, Javier De la Serna, Edith Szafer Glusman, Cathy Zhou, Jutta K. Neuenburg, Lynne Neumayr, Anita Szoke, James P. Dean, Paolo Ghia, Constantine S. Tam
Journal: Blood
Blood (2024) 144 (Supplement 1): 1869.
https://doi.org/10.1182/blood-2024-200936
Published: 2024
Journal Articles

Relapse after First-Line Fixed Duration Ibrutinib + Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study

Free
Paolo Ghia, William G. Wierda, Paul M. Barr, Thomas J. Kipps, Tanya Siddiqi, John N. Allan, Zoë Hunter, Cathy Zhou, Anita Szoke, James P. Dean, Constantine S. Tam
Journal: Blood
Blood (2023) 142 (Supplement 1): 633.
https://doi.org/10.1182/blood-2023-187128
Published: 2023
Journal Articles

Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study

Free
John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Bryone J. Kuss, Xavier C. Badoux, Jacqueline C. Barrientos, Alessandra Tedeschi, Stephen Opat, Ian W. Flinn, Eva Gonzalez Barca, Ryan Jacobs, Edith Szafer-Glusman, Cathy Zhou, Anita Szoke, William G. Wierda, Paolo Ghia, Constantine S. Tam
Journal: Blood
Blood (2022) 140 (Supplement 1): 224–227.
https://doi.org/10.1182/blood-2022-160338
Published: 2022
Journal Articles

Initiating First-Line (1L) Ibrutinib (Ibr) in Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched Population of ≥65 Years

Free
Paolo Ghia, Carolyn Owen, Jacqueline C. Barrientos, Paul M. Barr, Anthony R. Mato, Chunxue Shi, Anita Szoke, Chris Abbazio, Gabriel S. Krigsfeld, Jan A. Burger
Journal: Blood
Blood (2022) 140 (Supplement 1): 4159–4161.
https://doi.org/10.1182/blood-2022-163257
Published: 2022
Journal Articles

Relationship of JAK2 V617F Allelic Burden (AB) to Demographics, Disease Characteristics, and Response to Therapy in Persist-1, a Randomized Phase III Study of Pacritinib (PAC) Versus Best Available Therapy (BAT) in Patients (pts) with Primary and Secondary Myelofibrosis (MF)

Free
Alessandro M. Vannucchi, Adam Mead, Miklos Egyed, Anita Szoke, Aleksandr Suvorov, Andrew Perkins, Jiri Mayer, Peter Ganly, Harry C. Schouten, Patrizia Tosi, Charles Michael Farber, Pierre Zachee, Jean-Jacques Kiladjian, Jyoti Nangalia, James P. Dean, Huafeng Zhou, Jack W. Singer, Ruben A. Mesa, Claire N. Harrison
Journal: Blood
Blood (2016) 128 (22): 3131.
https://doi.org/10.1182/blood.V128.22.3131.3131
Published: 2016
Journal Articles

Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl

Free
John Mascarenhas, Ronald Hoffman, Moshe Talpaz, Aaron T. Gerds, Brady Stein, Vikas Gupta, Anita Szoke, Mark Drummond, Alexander Pristupa, Tanya Granston, Robert Daly, James P. Dean, Suliman Al-Fayoumi, Jennifer A. Callahan, Jack W. Singer, Jason Gotlib, Catriona Jamieson, Claire Harrison, Ruben Mesa, Srdan Verstovsek
Journal: Blood
Blood (2016) 128 (22): LBA-5.
https://doi.org/10.1182/blood.V128.22.LBA-5.LBA-5
Published: 2016